124 related articles for article (PubMed ID: 37247779)
1. Poor evidence is used to support commercial payers' coverage policies for shoulder arthroplasty.
Sudah SY; Faccone RD; Imam N; Patankar A; Manzi JE; Menendez ME; Nicholson A
J Shoulder Elbow Surg; 2023 Nov; 32(11):2222-2231. PubMed ID: 37247779
[TBL] [Abstract][Full Text] [Related]
2. What is the Level of Evidence Substantiating Commercial Payers' Coverage Policies for Total Joint Arthroplasty?
Austin MS; Ashley BS; Bedard NA; Bezwada HP; Hannon CP; Fillingham YA; Kolwadkar YV; Rees HW; Grosso MJ; Zeegen EN
J Arthroplasty; 2021 Aug; 36(8):2665-2673.e8. PubMed ID: 33867209
[TBL] [Abstract][Full Text] [Related]
3. Evidence Guiding Commercial Payer Coverage Criteria for Total Ankle Arthroplasty.
Kotlier JL; Fathi A; Ong MY; Yazditabar JM; Panoussi EE; Mayfield CK; Petrigliano FA; Liu JN; Peterson AB; Tan EW
Foot Ankle Orthop; 2024 Jan; 9(1):24730114241239310. PubMed ID: 38529013
[TBL] [Abstract][Full Text] [Related]
4. Mapping US commercial payers' coverage policies for medical interventions.
Chambers JD; Chenoweth MD; Neumann PJ
Am J Manag Care; 2016 Sep; 22(9):e323-8. PubMed ID: 27662396
[TBL] [Abstract][Full Text] [Related]
5. Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies.
Chambers JD; Pope EF; Wilkinson CL; Neumann PJ
J Manag Care Spec Pharm; 2018 Dec; 24(12):1240-1246. PubMed ID: 30479201
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS.
Chambers JD; Saret CJ; Anderson JE; Deverka PA; Douglas MP; Phillips KA
Int J Technol Assess Health Care; 2017 Jan; 33(4):534-540. PubMed ID: 29065945
[TBL] [Abstract][Full Text] [Related]
8. Private payer coverage policies for exome sequencing (ES) in pediatric patients: trends over time and analysis of evidence cited.
Douglas MP; Parker SL; Trosman JR; Slavotinek AM; Phillips KA
Genet Med; 2019 Jan; 21(1):152-160. PubMed ID: 29997388
[TBL] [Abstract][Full Text] [Related]
9. Variation in Private Payer Coverage of Rheumatoid Arthritis Drugs.
Chambers JD; Wilkinson CL; Anderson JE; Chenoweth MD
J Manag Care Spec Pharm; 2016 Oct; 22(10):1176-81. PubMed ID: 27668566
[TBL] [Abstract][Full Text] [Related]
10. Private payer coverage policies for ApoE-e4 genetic testing.
Arias JJ; Tyler AM; Douglas MP; Phillips KA
Genet Med; 2021 Apr; 23(4):614-620. PubMed ID: 33420342
[TBL] [Abstract][Full Text] [Related]
11. Shoulder replacement surgery for osteoarthritis and rotator cuff tear arthropathy.
Craig RS; Goodier H; Singh JA; Hopewell S; Rees JL
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012879. PubMed ID: 32315453
[TBL] [Abstract][Full Text] [Related]
12. Effects of Patient Comorbidities and Demographics on Episode-of-Care Costs Following Total Shoulder Arthroplasty.
Farronato DM; Pezzulo JD; Rondon AJ; Porrini S; McGonigal D; Getz CL; Davis DE
J Am Acad Orthop Surg; 2023 May; 31(9):451-457. PubMed ID: 36749879
[TBL] [Abstract][Full Text] [Related]
13. Economic Decision Model Suggests Total Shoulder Arthroplasty is Superior to Hemiarthroplasty in Young Patients with End-stage Shoulder Arthritis.
Bhat SB; Lazarus M; Getz C; Williams GR; Namdari S
Clin Orthop Relat Res; 2016 Nov; 474(11):2482-2492. PubMed ID: 27457626
[TBL] [Abstract][Full Text] [Related]
14. Commercial and public payer opioid analgesic prescribing policies: a case study.
Arfken CL; Tutag Lehr V
Subst Abuse Treat Prev Policy; 2021 Jan; 16(1):4. PubMed ID: 33407646
[TBL] [Abstract][Full Text] [Related]
15. Outcome of Revision Shoulder Arthroplasty After Resurfacing Hemiarthroplasty in Patients with Glenohumeral Osteoarthritis.
Rasmussen JV; Olsen BS; Al-Hamdani A; Brorson S
J Bone Joint Surg Am; 2016 Oct; 98(19):1631-1637. PubMed ID: 27707849
[TBL] [Abstract][Full Text] [Related]
16. How does depressive disorder impact outcomes in patients with glenohumeral osteoarthritis undergoing primary reverse shoulder arthroplasty?
Diamond KB; Gordon AM; Sheth BK; Romeo AA; Choueka J
J Shoulder Elbow Surg; 2023 Sep; 32(9):1886-1892. PubMed ID: 37044306
[TBL] [Abstract][Full Text] [Related]
17. The 50 Highest Cited Papers on Shoulder Arthroplasty.
Mercurio M; Cofano E; Familiari F; Corona K; Cerciello S; Gasparini G; Galasso O
Healthcare (Basel); 2022 Oct; 10(10):. PubMed ID: 36292447
[TBL] [Abstract][Full Text] [Related]
18. What are the costs of glenohumeral osteoarthritis in the year prior to a total shoulder arthroplasty (TSA)?
Malik AT; Bishop JY; Neviaser A; Jain N; Khan SN
Phys Sportsmed; 2020 Feb; 48(1):86-97. PubMed ID: 31213113
[No Abstract] [Full Text] [Related]
19. Value Analysis of Anatomic and Reverse Shoulder Arthroplasty for Glenohumeral Osteoarthritis with an Intact Rotator Cuff.
Polisetty TS; Colley R; Levy JC
J Bone Joint Surg Am; 2021 May; 103(10):913-920. PubMed ID: 33983149
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
